However, the use of anti-HER2 ADCs in the treatment of early HER2-low breast cancer is still far from implementation in the clinical practice, which may obscure the clinical implication of evolution of HER2-low in locally advanced breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.